JEMPERLI: A Treatment Option for Patients With Primary Advanced or Recurrent Endometrial Cancer Symposium
Activity Overview
GSK welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend the JEMPERLI: A Treatment Option for Patients With Primary Advanced or Recurrent Endometrial Cancer, an Industry Supported Symposium presented at the WAGO 2025 Annual Meeting on Thursday, June 19, 2025.
This is a non-CME program and is intended for healthcare professionals only.
Target Audience
Gynecologic and medical oncologists, oncology researchers, clinical trial coordinators, advanced practice providers, and other healthcare professionals involved in the management of ovarian cancer.Presented By
Lyndsay J. Willmott, MD, FACOGBanner University Medical Center
Paid consultant to GSK
Agenda
Endometrial Cancer Background
- Review the incidence of endometrial cancer and the importance of MMR/MSI biomarker testing
- Learn about the efficacy and safety data of JEMPERLI in combination with carboplatin and paclitaxel followed by JEMPERLI as a single agent for primary advanced or recurrent endometrial cancer from the RUBY Part 1 trial
- Review the Important Safety Information for JEMPERLI
This GlaxoSmithKline (GSK) promotional program is limited to US healthcare professionals (HCPs) only. Some state laws prohibit pharmaceutical manufacturers from providing meals or limit transfers of value to HCPs. Many employers (eg, hospitals, teaching institutions, government) also restrict what employees may accept from outside parties. Please do not accept any meal that violates the laws of the state(s) in which you are licensed or practice or the rules of your employer. GSK publicly discloses transfers of value as required by law, including the monetary value of meals and related expenses provided to attendees at this program.
